Dr. Jill Marie Jene, Head of Corporate Development at Miletus Biotechnology, brings over 20 years of experience in biopharmaceutical strategy, leadership, and dealmaking within the life sciences industry. Dr. Jene is focused on improving patients’ lives while creating value for shareholders and stakeholders. Throughout her career, Dr. Jene has amassed a deal sheet totaling over 50 closed transactions worth over $6 billion across multiple therapeutic areas, including oncology, immunology, neurology, pain, and women’s health.

Dr. Jene is an experienced executive in corporate strategy and business development. She served in senior leadership roles at Adamas Pharmaceuticals (acquired by Supernus), PDL Biopharma, twoXAR (now Aria), Depomed (now Assertio), Cell Genesys, 3M Pharmaceutical Division, and Baxter International, where she successfully led the creation and implementation of the corporate strategic plan while building out the business development pipeline.

She is currently the founder and principal of Jene Advisors, a biopharmaceutical advisory firm. She serves on the board of directors for Lipocine Inc., a biopharmaceutical company focused on neuroendocrine and metabolic disorders.

Earlier in her career, Dr. Jene held positions of increasing responsibility at Baxter International, the 3M Company (now part of Valeant), and Cell Genesys (acquired by Biosante).

Dr. Jene earned a B.S. from Bradley University, a M.S. and Ph.D. in chemistry from Northwestern University, and an MBA in strategic management from DePaul University.